| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 12/06/2007 | US20070280987 Bioactive polymers for imparting bioactive character to hydrophobic medical article surfaces |
| 12/06/2007 | US20070280959 Use Of Platelets Or Platelet Rich Plasma(Prp) |
| 12/06/2007 | US20070280958 homodimer-forming chemokines such as Chemokine (C-C motif) ligand 2 (CCL2) having a single amino acid substitution in the dimerization interface that alters the pattern of hydrogen bonds; for inflammatory, autoimmune, or infectious diseases |
| 12/06/2007 | US20070280957 Change of the Load State of Mhc Molecules |
| 12/06/2007 | US20070280954 Novel Immunomodulating Peptide |
| 12/06/2007 | US20070280950 Inflammatory Cytokine Inhibitors |
| 12/06/2007 | US20070280947 Tie Receptor and Tie Ligand Materials and Methods for Modulating Female Fertility |
| 12/06/2007 | US20070280940 Tweak as a Therapeutic Target for Treating Central Nervous System Diseases Associated with Cerebral Edema and Cell Death |
| 12/06/2007 | US20070280939 Prostatic Acid Phosphatase Antigens |
| 12/06/2007 | US20070280938 Peptides Derived from Natural Cytotoxicity Receptors and Methods of Use Thereof |
| 12/06/2007 | US20070280932 Binding to monoclonal antibodies; antitumor agents |
| 12/06/2007 | US20070280931 Antibody variants |
| 12/06/2007 | US20070280929 Adjuvant in the form of a lipid-modified nucleic acid |
| 12/06/2007 | US20070280927 Treatment Of Neurodegenerative Diseases By The Use Of Atp7a |
| 12/06/2007 | US20070280926 Sting kit apparatus and method of use |
| 12/06/2007 | US20070280925 Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| 12/06/2007 | US20070280924 Pharmaceutical Preparations For And Treatment Of Ocular Surface and Other Disorders |
| 12/06/2007 | US20070280923 Recombinant Fusion-Enzyme with Repair Activity on DNA Lesions Produced by UV Radiation; Its Usage, Preparation and Purification Method; A Method to Stabilize Enzymes and Treatment methods |
| 12/06/2007 | US20070280922 Combinations of human proteins to enhance viability of stem cells and progenitor cells |
| 12/06/2007 | US20070280921 recombinant silicatein- beta and silicatein- beta -fusion proteins from Suberites domuncula |
| 12/06/2007 | US20070280920 PHARMACEUTICAL COMPOSITION COMPRISING A FACTOR VIIa AND A FACTOR XIII |
| 12/06/2007 | US20070280918 Multitherapy Against Cancer |
| 12/06/2007 | US20070280917 Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| 12/06/2007 | US20070280916 Pharmaceutical Formulations Comprising Paraoxonase |
| 12/06/2007 | US20070280908 Treatment of diabetes with synthetic beta cells |
| 12/06/2007 | US20070280905 Prognosis and Systemic Therapy for Treating Malignancy |
| 12/06/2007 | US20070280904 Lectin-derived progenitor cell preservation factors and methods of use |
| 12/06/2007 | US20070280903 T1 Receptor-Like Ligand II and Uses Thereof |
| 12/06/2007 | US20070280902 Method for treating eye disease or conditions affecting the posterior segment of the eye |
| 12/06/2007 | US20070280886 Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr) |
| 12/06/2007 | US20070280880 Method for cell-specific targeting |
| 12/06/2007 | US20070280879 Therapeutic Use Of Rm1 Antigen |
| 12/06/2007 | US20070279454 Printing apparatus, printing method, and print head |
| 12/06/2007 | DE202006020194U1 G-CSF-Flüssigformulierung G-CSF liquid formulation |
| 12/06/2007 | DE102006026589A1 Verwendung eines Kollagens mit osteoinduktiven Wirkstoffen zur Behandlung von Sehnen- und/oder Bänderdefekten Use of a collagen with osteoinductive agents for the treatment of tendon and / or ligament defects |
| 12/06/2007 | DE102006025338A1 Verwendung eines Proteinkonzentrates Use of a protein concentrate |
| 12/06/2007 | DE102006025146A1 Peptide that modulates proteasome activity, e.g. for disease treatment, comprises a human protein sequence |
| 12/06/2007 | CA2820391A1 Recombinant or transgenic factor vii composition, each factor vii molecule having two n-glycosylation sites with defined glycan units |
| 12/06/2007 | CA2655665A1 Methods of use and nutritional compositions of touchi extract |
| 12/06/2007 | CA2653939A1 Immunostimulatory oligonucleotides and use thereof in pharmaceuticals |
| 12/06/2007 | CA2653925A1 Combination of amino acid solution and a gelatin derivative for inhibiting renal uptake |
| 12/06/2007 | CA2653920A1 Composition for controlling snoring, in the form of a nasal spray |
| 12/06/2007 | CA2653916A1 Nasal and buccal compositions for controlling snoring |
| 12/06/2007 | CA2653840A1 Method and compound for the treatment of valvular disease |
| 12/06/2007 | CA2653821A1 Controlled-release formulation |
| 12/06/2007 | CA2653600A1 Compositions and methods for detection and modulation of t cell mediated immune responses against viral vectors utilized for gene therapy |
| 12/06/2007 | CA2653313A1 Administration of the reg1 anticoagulation system |
| 12/06/2007 | CA2653288A1 Methods of modulating epithelial-mesenchymal transition and mesenchymal-epithelial transition in cells and agents useful for the same |
| 12/06/2007 | CA2653101A1 Compositions and methods for the delivery of nitric oxide |
| 12/06/2007 | CA2653077A1 N-oxides of kappa opioid receptor peptides |
| 12/06/2007 | CA2653072A1 Method for elevating prolactin in mammals |
| 12/06/2007 | CA2652907A1 Compositions and methods for treatment of diabetes |
| 12/06/2007 | CA2652815A1 Methods of treating stroke |
| 12/06/2007 | CA2652506A1 Glycopeptide antibiotic derivative |
| 12/06/2007 | CA2652496A1 Recombinant or transgenic factor vii composition, each factor vii molecule having two n-glycosylation sites with defined glycan units |
| 12/06/2007 | CA2651043A1 Compounds and compositions as channel activating protease inhibitors |
| 12/06/2007 | CA2647161A1 Probiotic strain and antimicrobial peptide derived therefrom |
| 12/05/2007 | EP1862549A2 Target of RNAIII activating protein (TRAP) |
| 12/05/2007 | EP1862547A1 Method of detecting mycoplasma |
| 12/05/2007 | EP1862546A1 Enhanced virus-mediated dna transfer |
| 12/05/2007 | EP1862544A1 Polypeptides capable of eliciting an immune reaction against cancer |
| 12/05/2007 | EP1862541A1 Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2 |
| 12/05/2007 | EP1862476A2 RGD-enriched gelatine-like proteins with enhanced cell binding |
| 12/05/2007 | EP1862475A1 Polymer conjugates of neublastin and methods of using same |
| 12/05/2007 | EP1862472A2 Chlamydia protein, gene sequence and uses thereof |
| 12/05/2007 | EP1862471A2 Pharmacologically active antiviral peptides and methods of their use |
| 12/05/2007 | EP1862182A2 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method |
| 12/05/2007 | EP1862174A1 Inhibitor for insulin polymer formation |
| 12/05/2007 | EP1862173A1 Promoter of regeneration of pancreatic cell, and promoter of insulin production in pancreatic cell |
| 12/05/2007 | EP1862172A1 Combination of amino acid solution and a gelatin for inhibiting renal uptake |
| 12/05/2007 | EP1862170A1 Protein formulation |
| 12/05/2007 | EP1862164A2 Dry powder for inhalation |
| 12/05/2007 | EP1861712A2 Extracting reagent for hydrophobic analyte in whole blood |
| 12/05/2007 | EP1861506A2 Cellulases, nucleic acids encoding them and methods for making and using them |
| 12/05/2007 | EP1861426A1 Immunogenic molecules |
| 12/05/2007 | EP1861423A1 Molecules and chimeric molecules thereof |
| 12/05/2007 | EP1861422A2 Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
| 12/05/2007 | EP1861419A1 Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems |
| 12/05/2007 | EP1861417A2 Dimeric or multimeric microproteins |
| 12/05/2007 | EP1861416A1 Obestatin and its uses |
| 12/05/2007 | EP1861125A2 Conjugates of an hgh moiety and peg derivatives |
| 12/05/2007 | EP1861121A1 Hiv vaccine composition |
| 12/05/2007 | EP1861116A2 Vegf antagonist formulations |
| 12/05/2007 | EP1861115A2 Semi-synthetic glycopeptides with antibiotic activity |
| 12/05/2007 | EP1861114A2 Compositions comprising modulators of g-protein-coupled receptor for treatment of macular degeneration |
| 12/05/2007 | EP1861094A2 Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
| 12/05/2007 | EP1684794A4 Altering animal waste composition |
| 12/05/2007 | EP1678198A4 Side chain deuterated amino acids and methods of use |
| 12/05/2007 | EP1670415A4 Animal model for protease activity and liver damage |
| 12/05/2007 | EP1635692A4 Monitoring immunologic, hematologic and inflammatory diseases |
| 12/05/2007 | EP1492876B1 Cationic amphiphiles for intracellular delivery of therapeutic molecules, composition, process and use thereof |
| 12/05/2007 | EP1339440B1 An implantable or insertable therapeutic agent delivery device |
| 12/05/2007 | EP1305399B1 Bacillus subtilis var. chungkookjang producing high molecular weight poly-gamma-glutamic acid |
| 12/05/2007 | EP1292278B1 Preparations that contain an extract of the plant pistia stratiotes |
| 12/05/2007 | EP1169294B1 Pharmaceutical compounds |
| 12/05/2007 | EP1017318B1 Method of imaging cell death in vivo |
| 12/05/2007 | EP0941252B1 Anti-p53 single-chain antibody fragments and their uses |
| 12/05/2007 | EP0932418B1 Method for recombinant adeno-associated virus-directed gene therapy |
| 12/05/2007 | EP0931149B1 A novel haemopoietin receptor and genetic sequences encoding same |
| 12/05/2007 | EP0760675B2 Compositions comprising dna damaging agents and p53 |